icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Economic Burden of Chronic Hepatitis C (CHC) in Medicaid and Commercially Insured Patients in the United States
 
 
  Reported by Jules Levin
AASLD Annual Meeting 2017, Washington, DC, USA, October 20-24
 
Chizoba Nwankwo1; Shelby L. Corman2; Jinan Liu1
1Merck & Co., Inc., Kenilworth, NJ, USA; 2Pharmerit International,
Bethesda, MD, USA
 
from Jules: I'm not convinced this study captured the entire healthcare costs to Medicaid vs commercial insurance. Undiagnosed HCV infection & not being treated is likely to be greater in Medicaid, IDUs and marginalized communities, and drug users are more likely to not be diagnosed or treated, thus their associated healthcare costs may not be included in this analysis; end of life costs may not even be associated with HCV infection because it may not be in the patient record.

AASDL1

AASDL2

AASDL3